Abbvie announces acquisition of approval for chronic hepatitis C oral treatment VIEKIRAX/EXVIERA

Published: 2017-03-21 15:32:51

Updated: 2017-03-21 15:32:51

Abbvie Korea(CEO Hong-Ki Yoo) announced the Korea Ministry of Health and Welfare approved VIEKIRAX(generic name: ombitasvir, paritaprevir, ritonavir) and EXVIERA(generic name: sasabuvir) as chronic hepatitis C treatment on the 17^th. VIEKIRAX and EXVIERA acquired approval as the treatment of chronic hepatitis C genotype 1 for patients with compensatory cirrhosis of the liver. Depending on genoty...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.